.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Chubb
US Army
QuintilesIMS
Dow
Chinese Patent Office
Citi
Baxter
Mallinckrodt
Johnson and Johnson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:.beta.2-adrenoceptor agonists
Abstract: Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s): Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin A (Horsham, GB), Beattie; David (Horsham, GB)
Assignee: Novartis AG (Basel, CH)
Filing Date:Mar 07, 2005
Application Number:11/074,400
Claims:1. A combination comprising: (a) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one, in free or salt or solvate form; and (b) a steroid.

2. The combination of claim 1 wherein the steroid is selected from the group consisting of budesonide, beclamethosone, fluticasone and mometasone.

3. The combination of claim 1 wherein (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate.

4. The combination of claim 1 wherein (b) is mometasone.

5. The combination of claim 1 wherein (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy- 1H-quinolin-2-one maleate and (b) is mometasone.

6. A pharmaceutical composition comprising a combination of claim 1 and a pharmaceutically acceptable carrier.

7. A method of treating a patient with an obstructive or inflammatory airways disease comprising administering to the patient in need of such treatment a therapeutically effective amount of the combination of claim 1.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
US Department of Justice
Harvard Business School
UBS
AstraZeneca
Express Scripts
Dow
Chinese Patent Office
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot